Podcast: Dr Susana Benerjee says more women should be getting PARP inhibitors in the first-line setting
11 Oct 2019
Podcast: Dr Susana Benerjee says more women should be getting PARP inhibitors in the first-line setting
Results of the registrational phase I/II ARROW trial of pralsetinib, presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, reveal overall response rates (ORRs) of ≥60 percent in pretreated and treatment-naïve RET-mutated (RETmut) medullary thyroid cancer (MTC) patients.
Results of the registrational phase I/II ARROW trial of pralsetinib, presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, reveal overall response rates (ORRs) of ≥60 percent in pretreated and treatment-naïve RET-mutated (RETmut) medullary thyroid cancer (MTC) patients.